Rituximab in Kidney-Limited Microscopic Polyangiitis: A Case Report

Madhavaram, Anvitha R.1*, Nezam, Altorok MD2

1College of Medicine and Life Sciences, The University of Toledo, Toledo, OH 43614
2Division of Rheumatology, Department of Medicine, The University of Toledo, Toledo, OH 43614

*Corresponding author: Anvitha.Madhavaram@rockets.utoledo.edu

Keywords: Microscopic Polyangiitis, Rituximab

Published: 14 December 2023

Background: Microscopic polyangiitis (MPA) is an immune complex mediated necrotizing vasculitis. The diagnosis is based on symptoms, including rapidly progressive glomerulonephritis, peripheral nerve disorder, lung abnormalities, and positive MPO-ANCA findings (1). The pathophysiology involves formation of neutrophil extracellular traps in the kidneys, which correlate with ANCA affinity for MPO and disease activity (2). Rituximab has been used in cases where conventional cyclophosphamide therapy may not be suitable (3).

Case Presentation: A 78-year-old white male with a past medical history of gout and type 2 diabetes mellitus, presented with general weakness. Laboratory testing revealed serum creatinine of 5.2 mg/dl (normal <1.3 mg/dl) on presentation. He underwent kidney biopsy which demonstrated crescentic pauci-immune glomerulonephritis. He was treated with two doses of rituximab 1 gram, two weeks apart every 6 months for the past year. Upon presentation, he underwent dialysis for 2 months. After two years of treatment, laboratory evaluations reveal a stable creatinine of 1.77 and MPO antibody titers persistently elevated above 8. The patient responds well to Rituximab treatment, with stable renal function and no signs of extrarenal organ involvement. The plan is to continue treatment for a minimum of five years due to his consistently elevated MPO titer.

Discussion: Rituximab, a monoclonal antibody against CD20, is used as monotherapy for MPA to induce remission or alongside prednisone in severe MPA [4]. Given the patient's age, his remarkably kidney-limited disease, and favorable side effect profile, rituximab infusions were initiated over conventional chronic corticosteroids and cyclophosphamide therapy.

This case report highlights the kidney-limited form of MPA, and aims to underscore the utility of rituximab as a treatment option for kidney-limited MPA. Further research is needed to understand long-term outcomes, optimize management, and establish guidelines for management of similar cases.
References


